Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 6/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42808 | 0.88 | ALDH1A1 (0.58) | ALDH1A1AKR1C3HPGDNPC1RAB9A | |
| SCHEMBL182890 | 0.86 | ALDH1A1 (0.51) | ALDH1A1AKR1C3HPGDNPC1RAB9A | |
| SCHEMBL136822 | 0.77 | NPC1 (0.60) | ALDH1A1HPGDDDB1CRBNNPC1 | |
| SCHEMBL28499191 | 0.76 | ALDH1A1 (0.38) | ALDH1A1AKR1C3HPGDDDB1CRBN | |
| SCHEMBL25846387 | 0.76 | DDB1 (0.60) | ALDH1A1AKR1C3HPGDDDB1CRBN | |
| SCHEMBL4313256 | 0.75 | SLC6A2 (0.45) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL19751 | 0.75 | F10 (0.50) | — | |
| SCHEMBL4240116 | 0.74 | KMT2A (0.53) | ALDH1A1AKR1C3HPGDDDB1CRBN | |
| SCHEMBL4733957 | 0.74 | IDO1 (0.50) | ALDH1A1AKR1C3HPGDDDB1CRBN | |
| SCHEMBL12615119 | 0.74 | RAB9A (0.51) | ALDH1A1AKR1C3NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | claimed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | ALDH1A1 1849/4885AKR1C3 1900/4885HPGD 1007/4885 |
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | ALDH1A1 948/4885AKR1C3 2117/4885HPGD 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.